Eli Lilly and Company (LLY)
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (80%) **Content type:** Clinical